Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 26-week, Multicenter, Open-label Phase 3b Study of the Safety and Tolerability of Quetiapine Fumarate (SEROQUEL™) Immediate-release Tablets in Daily Doses of 400 mg to 800 mg in Children and Adolescents With Bipolar I Disorder and Adolescents With Schizophrenia (Abbreviated)

NCT00227305 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT00227305
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00227305 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 26-week, Multicenter, Open-label Phase 3b Study of the Safety and Tolerability of Quetiapine Fumarate (SEROQUEL™) Immediate-release Tablets in Daily Doses of 400 mg to 800 mg in Children and Adolescents With Bipolar I Disorder and Adolescents With Schizophrenia (Abbreviated)
Lead sponsor
AstraZeneca
Phase
Phase 3
Overall status
Completed
Start date
August 31, 2004
Completion date
December 31, 2007
Enrollment
381 (actual)
Sites
48

Conditions

As the registry lists them; a condition with its own page is linked.

bipolar i disorder, schizophrenia